secwatch.observer — SEC 8-K summary
======================================

Issuer:     Disc Medicine, Inc. (IRON)
CIK:        0001816736
Form:       8-K
Filed at:   2026-02-17T23:59:59+00:00
Accession:  0001193125-26-053066
Event type: regulatory
Sentiment:  negative
Materiality: 0.90
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA issues Complete Response Letter for Disc Medicine's bitopertin NDA in erythropoietic protoporphyria
--------------------------------------------------------------------------------

- FDA issued a Complete Response Letter on February 13, 2026 for bitopertin NDA for erythropoietic protoporphyria (EPP).
- The CRL indicates FDA will not approve the NDA in its current form, typically requiring additional data or analyses.
- Disc Medicine hosted a conference call on February 17, 2026 to discuss the CRL and next steps; webcast available for 30 days.
- Bitopertin is Disc Medicine's lead product candidate; this regulatory setback materially impacts the company's pipeline.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1816736/000119312526053066/0001193125-26-053066-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1816736/000119312526053066/iron-20260217.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-053066

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer